Clinical trial teams have long relied on the IWQOL Lite CT (Impact of Weight on Quality of Life–Lite Clinical Trials Version) to measure the impact of weight-management therapies for patients from a quality of life perspective — not just how much patients weigh on the scale.
A new study in Clinical Obesity just expanded that value considerably.
The latest findings
The IWQOL-Lite-CT works well outside clinical trials. Internal consistency, test–retest reliability, and construct validity all held up in a large US observational study. For sponsors and CROs, that changes what’s possible.
The bigger opportunity
Research into obesity and metabolic disease is increasingly happening outside the trial setting — in observational studies, real-world evidence programs, longitudinal registries, comparative effectiveness studies, and post-authorization safety studies. Until now, teams running those programs have had to choose between a general instrument and one that fits the setting.
That tradeoff is now largely gone.
What the data actually showed
The study compared baseline scores of the IWQOL-Lite-CT from a phase 3a clinical trial population with baseline scores from a US observational, longitudinal survey of adults with obesity. Participants in the observational survey scored more than 20 points lower on every composite score — Total, Physical, Physical Function, and Psychosocial—indicating that participants in the observational survey reported more weight-related limitations than those in the clinical trial.
That gap is the key finding. The instrument is sensitive enough to capture the burden of disease in patients who will never meet clinical trial inclusion criteria. The patients who make up most of the real world.
What it means for your evidence strategy
With the IWQOL-Lite-CT, you can use the same instrument across your interventional and non-interventional programs. Baseline data from an observational registry becomes directly comparable to outcomes from your phase 3 trial. The longitudinal story you tell about a therapy’s impact on patient functioning gets stronger — because it’s built on a single validated measure across the full arc of development and post-market research.
Explore Greenlight’s Exclusive COA Library
IWQOL-Lite-CT is part of Greenlight’s exclusive Clinical Outcome Assessment (COA) Library, which includes validated patient-reported, clinician-reported, observer-reported, and performance outcome measures used across therapeutic areas.
Explore IWQOL-Lite-CT and the full COA Library:
https://greenlighthealth.com/solutions/clinical-outcome-assessments/coa-library/
Greenlight helps life sciences organizations access and implement scientifically validated outcome measures that support clinical development, real-world evidence generation, and patient-centered research.
